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Purpose: To investigate the signaling pathways involved in interleukin (IL)-17A -mediated production of interleukin 8
(CXCL8), chemokine (C-C motif) ligand 2 (CCL2), and interleukin 6 (IL-6) by ARPE-19 cells, a spontaneously arisen
cell line of retinal pigment epithelium (RPE).
Methods: Flow cytometry analysis and western blot were used to detect the phosphorylation of extracellular signal-
regulated kinases 1/2 (Erk1/2), p38 mitogen activated protein kinase (MAPK) and protein kinase B (PKB; Akt) in
ARPE-19 cells stimulated with IL-17A. These cells were further pretreated with a series of kinase inhibitors and followed
by incubation with IL-17A. CXCL8, CCL2, and IL-6 in the supernatant were quantified by enzyme-linked immunosorbent
assay (ELISA).
Results: Coculture of ARPE-19 cells with IL-17A resulted in significant increases in Erk1/2, p38 MAPK, and Akt
phosphorylation. Inhibition of p38MAPK, phosphoinositide 3-kinase (PI3K)-Akt and nuclear factor-kappaB (NF-κB),
with the inhibitors SB203580, LY294002 and pyrrolydine dithiocarbamate (PDTC) respectively, reduced IL-17 (100 ng/
ml) mediated production of CXCL8, CCL2, and IL-6 in a concentration dependent manner. Inhibition of Erk1/2 with
PD98059 decreased the expression of the tested three inflammatory mediators when using low doses of IL-17A (0–10 ng/
ml) but not at higher concentrations.
Conclusions: IL-17A-induced production of inflammatory mediators by ARPE-19 cells involves Erk1/2, p38MAPK,
PI3K-Akt and NF-κB pathways.
Uveitis is a common intraocular inflammatory disease.
Recent studies have shown that helper T lymphocyte (Th)17
cells  are  implicated  in  the  pathogenesis  of  this  serious
intraocular disorder [1,2]. They have been identified as a
subset  of  T-helper  lymphocytes  characterized  by
predominantly  producing  interleukin  (IL)-17A  [3,4].
Growing  evidence  suggests  that  Th17  cells  trigger
inflammatory responses primarily via IL-17A [5].
A  recent  study  showed  an  increased  expression  of
IL-17A  mRNA  in  the  retina  of  mice  with  experimental
autoimmune uveoretinitis (EAU), a classical model for human
autoimmune  uveitis  [1].  IL-17A  protein  was  furthermore
found  to  be  highly  expressed  by  peripheral  blood
mononuclear  cells  (PBMCs)  from  uveitis  patients  [6,7].
IL-17A is a proinflammatory cytokine which is reflected by
its ability to promote a variety of cells to produce chemokines
and  proinflammatory  cytokines  including  interleukin-8
(CXCL8), CCL2, and IL-6 [8].
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The  neuroectodermally-derived  retinal  pigment
epithelium (RPE), strategically positioned at the blood-retinal
barrier, is considered to play an important role in posterior
ocular  inflammation  due  to  its  ability  to  secrete  several
inflammatory mediators [9]. CXCL8, CCL2, and IL-6 are
three major inflammatory mediators produced by RPE cells
in response to various stimuli [9]. Several studies have shown
that these mediators are involved in the pathogenesis of uveitis
[10-12].  CXCL8  is  a  chemoattractant  and  activator  of
neutrophils, whereas CCL2 is a chemoattractant and activator
for  lymphocytes  and  monocytes.  These  two  chemokines
mediate neutrophil, lymphocyte and monocyte/macrophage
infiltration into tissues. IL-6 is a pleiotropic proinflammatory
cytokine. The overexpression of IL-6 may intensify the local
immune and inflammatory response.
In a previous study we showed that IL-17A is a potent
stimulus for CXCL8, CCL2, and IL-6 secretion by ARPE-19
cells [13], the spontaneously arisen human RPE-derived cell
line which has been extensively used in the past decades to
investigate the role of this cell layer in the pathogenesis of
ocular  posterior  diseases  including  uveitis.  It  has  been
reported  that  activation  of  extracellular  signal-regulated
kinases 1/2 (Erk1/2), p38 mitogen activated protein kinase
Molecular Vision 2011; 17:3072-3077 <http://www.molvis.org/molvis/v17/a330>
Received 26 October 2011 | Accepted 15 November 2011 | Published 23 November 2011
© 2011 Molecular Vision
3072(MAPK),  and  phosphoinositide  3-kinase  (PI3K)-Akt  is
involved in the IL-17A induced response of certain cell types
[14-17]. However, the signaling events leading to CXCL8,
CCL2,  and  IL-6  protein  expression  by  IL-17A-induced
ARPE-19 cells have not yet been characterized. In this study,
we therefore investigated the role of Erk1/2, p38 MAPK, and
PI3K-Akt  in  IL-17A-induced  CXCL8,  CCL2,  and  IL-6
protein production.
METHODS
Cell culture: Human ARPE-19 cells were obtained from the
American type culture collection (ATCC, Manassas, VA), and
cells between passages 16 and 20 were used for experiments.
The  cells  were  cultured  in  Dulbecco’s  modified  Eagle
medium/F12(DMEM/F12 (Invitrogen, Beijing, China) with
10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA), 100
U/ml penicillin, and 100 μg/ml streptomycin in a humidified
incubator at 37 °C in 5% CO2. The cells were passed every 4
to 5 days by trypsinization and were seeded into Corning
flasks (Corning, Lowell, MA) at 1.2×106 cells/flask, resulting
in completely confluent (≈1.2×106 cells/flask) cultures in 4
days.
Flow cytometry analysis: Flow cytometry analysis was used
to detect the activation state of signaling pathway kinases in
ARPE-19  cells.  Confluent  ARPE-19  cells  maintained  in
serum-free medium for 24 h were cultured with or without 100
ng/ml  IL-17A  at  37  °C  in  5%  CO2  for  the  detection  of
phospho-Erk1/2, p38, and Akt, respectively. We conducted
simultaneous  staining  of  ARPE-19  cells  for  intracellular
phosphorylated Erk1/2, p38, and Akt proteins according to the
protocol recommended by Cell Signaling Technology (Cell
Signaling Technology, Beverly, MA). Briefly, ARPE-19 cells
were  fixed  in  4%  formaldehyde  for  10  min  at  room
temperature and permeabilized in methanol for 30 min on ice.
We used the phospho-specific Abs anti-phospho-Erk1/2-PE,
anti-phospho-p38MAPK-Alexa Fluor 488 and anti-phospho-
Akt-Alexa Fluor 488 for intracellular staining (Cell Signaling
Technology). Isotype-matched irrelevant Abs were used as
controls.  Phosphorylation  of  the  three  proteins  for  both
unstimulated and stimulated ARPE-19 cells was evaluated by
flow cytometry and expressed as mean fluorescence intensity
(MFI). All experiments were repeated three times.
Western blot: ARPE-19 cells were serum starved in DMEM/
F12 without FBS for 24 h, then treated with or without 100
ng/ml  IL-17A  for  7,  15,  or  30  min.  The  cells  were
subsequently rinsed with ice-cold PBS and lysed with lysis
buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 2 mM
EDTA, and 100 μM phenylmethylsulfonylfluoride. The cell
lysate  was  centrifuged  and  the  supernatant  was  collected.
Protein concentration was determined with a protein assay
(Bio-Rad, Richmond, CA). Laemmli gel loading buffer was
added to the lysate and boiled for 7 min, after which proteins
were separated on an SDS-polyacrylamide gel. Proteins were
transferred  to  polyvinylidene  difluoride  membranes
(Millipore, Bedford, MA), blocked by 5% skim milk at 37 °C
for 2 h, and incubated with the primary phosphorylated or total
antibodies  against  Erk1/2,  p38MAPK,  and  Akt  (Cell
Signaling  Technology)  at  4  °C  for  16  h,  followed  by  a
horseradish  peroxidase-conjugated  secondary  antibody  at
Figure 1. Effects of IL-17A on phosphorylation of Erk1/2, p38MAPK, or Akt in ARPE-19 cells. ARPE-19 cells were incubated without or
with 100 ng/ml IL-17A whereafter the degree of phosphorylation of Erk1/2, p38 and Akt was measured. The amounts of intracellular
phosphorylated signaling molecules in 10,000 permeabilized ARPE-19 cells were measured by flow cytometry. A representative example
and MFI result expressed as the mean±SD of three independent experiments are shown for the phosphorylation of Erk1/2 (20 min stimulation;
A), p38 MAPK (20 min stimulation; B), and Akt (20 min stimulation; C) in response to IL-17A (thick line histograms). Thin line histograms
indicate basal phosphorylation in the absence of IL-17A. Western blot analysis of phosphorylated Erk1/2, p38MAPK or Akt was performed
on ARPE-19 cells stimulated with or without 100 ng/ml of IL-17A for the indicated time periods. Results are representative of three separate
experiments.
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307337 °C for 1 h. The membranes were further developed using
a  chemiluminescent  detection  kit  (Cell  Signaling
Technology). Each stimulation experiment was repeated three
times.
Enzyme-linked  immunosorbent  assay  (ELISA):  ARPE-19
cells  were  maintained  in  DMEM/F12  medium  containing
10% FBS for 4 days to become confluent. Before treatment
with signaling inhibitors, cells were serum-starved for 24 h in
DMEM/F12 without FBS. ARPE-19 cells were pretreated
with or without an inhibitor to Erk1/2 (PD98059 at 50, 25, and
10 μM), p38MAPK (SB203580 at 25, 10, and 1 μΜ), PI3K
(LY29400 at 25, 10, and 1 μΜ) or NF-κB (PDTC at 50, 25,
and 10 μM; all from Sigma-Aldrich, St. Louis, MO) for 2 h,
followed by incubation with or without recombinant IL-17A
(R&D Systems, Minneapolis, MN) for 24 h. The supernatants
were collected and centrifuged to remove particulates and
stored at −70 °C until analysis. CXCL8, CCL2, and IL-6 were
measured  using  human  commercially  available  ELISA
development kits (Duoset; R&D Systems). Each stimulation
experiment was repeated four times.
Statistical analyses: All data are expressed as means±SD.
Statistical  significance  of  changes  was  determined  by  the
Student’s t-test. A p<0.05 was considered to be statistically
significant for all experiments.
RESULTS
Effect  of  IL-17A  on  Erk1/2,  p38MAPK,  and  Akt
phosphorylation:  To  investigate  the  early  molecular
mechanisms whereby IL-17A stimulates the production of
CXCL8, CCL2, and IL-6, ARPE-19 cells were incubated for
10  or  20  min  with  100  ng/ml  IL-17A.  The  level  of
phosphorylated Erk1/2, p38MAPK, and Akt was evaluated by
measuring  mean  fluorescence  intensity  (MFI)  with  flow
cytometry. The result revealed that the MFI of phosphorylated
Erk1/2,  p38MAPK  and  Akt  significantly  increased  in
ARPE-19 cells stimulated by 100 ng/ml IL-17A as compared
to unstimulated cells. Examples of phosphorylated specific
intracellular staining are shown in Figure 1A-C. Additionally,
western blot analysis was performed to verify the activation
of these protein kinases. The samples were immunoblotted
with antibodies against the phosphorylated form of Erk1/2,
p38MAPK,  and  Akt.  As  shown  in  Figure  1D-F,  IL-17A
increased the phosphorylation of Erk1/2 and p38 MAPK by 7
min and remained elevated up to 30 min in these experiments.
The  expression  of  total-phosphorylated  Erk1/2  was  not
affected. Similarly, IL-17A activated Akt within 7 min. The
phosphorylation of Akt reached a maximum at 15 min and no
further increase was observed at later time points. The levels
of  total  Akt  remained  generally  constant.  Thus  IL-17A
activates Erk1/2, p38, and Akt in ARPE-19 cells.
Effects of signaling inhibitors on CXCL8, CCL2, and IL-6
production induced by IL-17A: To confirm the role of Erk1/2,
p38MAPK, Akt, and NF-κB activation in the production of
CXCL8, CCL2, and IL-6 by ARPE-19 cells stimulated with
100  ng/ml  IL-17A,  we  investigated  the  effect  of  Erk1/2,
p38MAPK, Akt, and NF-κB inhibitors. As shown in Figure
2, IL-17A caused a 13.1, 4.5, and 5.9 fold secretion of CXCL8,
CCL2, and IL-6 over basal levels, which was considered as
100%.  SB203580,  an  inhibitor  of  p38MAPK,  decreased
IL-17A-induced CXCL8, CCL2, and IL-6 production in a
dose-dependent manner, resulting in levels of 69±8%, 59±7%,
and 47±16%, respectively. Similarly, LY294002 and PDTC,
inhibitors  of  PI3K/Akt  and  NF-κB  also  dose-dependently
inhibited the expression of CXCL8, CCL2, and IL-6. The
levels  following  incubation  with  LY29400  were  75±5%,
64±12%, and 65±7%. The maximum levels following PDTC
were  80±7%,  70±10%,  and  78±8%.  The  aforementioned
inhibitors  also  markedly  repress  the  basal  secretion  of
CXCL8, CCL2, and IL-6 by ARPE-19 cells in the absence of
IL-17A (data not shown). PD98059, an inhibitor of Erk1/2 did
not affect the production of the three tested inflammatory
mediators when using a dose of 100 ng/ml of IL-17A. A
separate  experiment  using  lower  concentrations  of  IL17A
showed that PD98059 was able to inhibit the production of
these mediators when the concentration of IL-17A used to
stimulate the cells was lower than 50 ng/ml (Figure 3).
DISCUSSION
In this study, we demonstrated that IL-17A is able to enhance
the phosphorylation of Erk1/2, p38MAPK, and Akt in RPE
cells. The expression of IL-17A-induced CXCL8, CCL2, and
IL-6 was decreased in these cells by SB203580, LY294002,
and PDTC, inhibitors of p38MAPK, PI3K-Akt, and NF-κB,
respectively, in a concentration-dependent manner. We also
found PD98059, the inhibitor of Erk1/2 altered the expression
of IL-17A-induced inflammatory mediators, depending on the
concentration of IL-17A. This study is a continuation of a
previous study to determine the intracellular mechanisms of
IL-17A-mediated production of CXCL8, CCL2, and IL-6 by
RPE cells [13].
Accumulating evidence shows that MAPK activation is
an important signaling event in the response of RPE cells to
proinflammatory cytokines such as IL-1β and tumor necrosis
factor  (TNF)-α  [18].  We  found  that  IL-17A  induces
phosphorylation  of  Erk1/2  and  p38  MAPK  in  RPE  cells,
which  is  in  accordance  with  earlier  findings  in  articular
chondrocytes  [19]  and  cardiac  fibroblasts  [20].  We  also
showed that PD98059 and SB203580, specific inhibitors of
Erk1/2  and  p38MAPK,  reduced  IL-17A-induced  CXCL8,
CCL2,  and  IL-6  production  by  RPE  cells,  indicating  that
Erk1/2 and p38MAPK are involved in this process. These
findings are also in accordance with earlier findings using lung
microvascular endothelial cells [14], mesangial cells [15], and
human  pancreatic  periacinar  myofibroblasts  [16].  It  is
worthwhile to point out that the PD98059 mediated inhibition
of the release of the tested three inflammatory mediators was
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observation  is  consistent  with  earlier  findings  whereby
PD98059  was  also  not  able  to  inhibit  IL-17A  mediated
induction  of  CXCL8  mRNA  production  by  fibroblast-like
synoviocytes [21]. These data suggest that Erk1/2 may not be
the  major  intracellular  molecular  signaling  pathway
regulating  the  IL-17A-mediated  production  of  CXCL8,
CCL2, and IL-6 in non-immune type cells such as the RPE
cell or synoviocyte.
It  has  previously  been  shown  that  PI3K  and  its
downstream  mediator  Akt  regulate  the  production  of
inflammatory  mediators  in  response  to  proinflammatory
Figure 2. Effects of signaling inhibitors on IL-17A-induced CXCL8,
CCL2, and IL-6 production in ARPE-19 cells. Cells were pretreated
with PD98059 (PD), SB203580 (SB), LY29400 (LY) or PDTC at
the indicated concentrations for 2 h, followed by incubation with or
without  100  ng/ml  IL-17A  for  24  h.  Secreted  cytokines  in
supernatants were determined by ELISA. Values are expressed as
the mean±SD of four independent experiments. *p<0.05, compared
with the values in the absence of inhibitors.
cytokines [22,23]. Akt is activated by a variety of cell surface
receptors that when stimulated induce the activation of PI3K.
Figure 3. Effects of PD98059 on the expression of CXCL8, CCL2,
and  IL-6  in  ARPE-19  cells  simulated  with  or  without  different
concentration IL-17A. Cells were cultured with or without 50 μΜ
PD98059 (PD) for 2 h, followed by incubation with or without 1, 10,
and 50 ng/ml IL-17A for 24 h. Secreted cytokines in supernatants
were determined by ELISA. Values are expressed as the mean±SD
of four independent experiments. *p<0.05, compared with the values
in the absence of inhibitors.
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(PIP3) which in turn activates Akt. In the present study, we
demonstrated that activation of the PI3K-Akt pathway by
IL-17A is necessary for CXCL8, CCL2, and IL-6 protein full
expression in RPE cells. These results are consistent with
other  findings  in  human  airway  epithelial  cells  [17],
fibroblasts  and  macrophages  obtained  from  rheumatoid
arthritis synovial tissue [17,24]. In contrast to our data, the
PI3K/Akt pathway was only involved in the expression of
CCL2, not CXCL8 in human RPE following stimulation by
IL-1β  or  TNF-α  [25].  The  discrepancy  may  be,  at  least
partially, explained by the nature of the stimulus [25].
The activation of transcriptional factor NF-κB plays a
central role in the induction of inflammatory mediators. The
promoter regions of the human CXCL8, CCL2, and IL-6 genes
have been cloned and have been shown to contain consensus
binding  motifs  for  NF-κB  [26].  Our  results  showed  that
PDTC, an inhibitor of NF-κB, significantly inhibited IL-17-
induced  CXCL8,  CCL2,  and  IL-6  production  in  RPE
cells,suggesting that NF-κB activation was responsible for the
expression of these inflammatory mediators. Similar results
have been observed using a variety of other cell types [16,
17,27].
In conclusion, we have demonstrated that p38MAPK,
PI3K-Akt, and the transcription factor NF-κB are involved in
IL-17-induced CXCL8, CCL2, and IL-6 release in ARPE-19
cells.  Knowledge  concerning  the  mechanisms  whereby
IL-17A regulates the secretion of inflammatory mediators by
RPE cells may increase our insight in the pathogenesis of
posterior  uveitis  and  delineating  the  transactivation
mechanisms may help to identify new therapeutic targets.
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